Business Wire

Canada Growth Fund to Invest up to US$100 Million in Svante to Accelerate Growth

Share

Canada Growth Fund Inc. (“CGF”) and Svante Technologies Inc. (“Svante” or the “Company”), a leading global carbon capture and removal solutions provider headquartered in Vancouver, Canada, announced today a financing commitment of up to US$100 million to accelerate the development and construction of Svante’s commercial carbon capture and removal projects in Canada and the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815708357/en/

Claude Letourneau, Svante's President & CEO at Svante's World Headquarters, the Centre of Excellence for Carbon Capture & Removal in Vancouver, BC (Photo: Business Wire)

CGF has a mandate to invest in Canadian clean technology businesses that are scaling technologies currently in the commercialization stage of development. Svante is a leading developer of carbon capture and removal technology, with significant potential to accelerate emissions reductions in hard-to-abate sectors worldwide. CGF’s investment enables the Company to focus on its first-of-a-kind (FOAK) deployment opportunities and will encourage the business to prioritize opportunities in its Canadian pipeline. CGF’s capital is supporting ongoing Canadian operations and will encourage Svante to accelerate the delivery of projects domestically and internationally, leveraging their Canadian IP and manufacturing capabilities.

“CGF is working to accelerate the deployment of key Canadian carbon capture technologies, and to scale the manufacturing and export of promising solutions to showcase Canadian technologies internationally,” said Patrick Charbonneau, President and CEO of Canada Growth Fund Investment Management Inc. (“CGF Investment Management”). “Svante has a tremendous market opportunity, globally and here at home, and we look forward to supporting this company in its growth.”

CGF will fund its investment in two tranches: (i) an initial tranche of US$50 million will be used to accelerate and de-risk FOAK commercial projects currently underway and (ii) a potential second tranche expected to be tied to project-specific requirements to match Svante’s capital needs for the development and construction of projects alongside the Company’s co-development partners.

Claude Letourneau, Svante’s President and CEO, said: “We are delighted with this investment by CGF. It is transformational for Svante and complements the US$145 million capital investment made in our new carbon capture and removal filter manufacturing facility under construction in Vancouver. This will strengthen our Integrated Project Development Services offering to help our customers de-risk FOAK projects by providing both our in-house project development advisory expertise and financing. This new offering bridges the gap for our customers as it enables them to reach final investment decision.”

Transaction Highlights

  • CGF will invest up to US$100M in Svante via convertible note(s), aimed at advancing the development of Svante’s innovative carbon capture technology.
  • The investment will be made in two tranches: the first tranche of US$50M will be disbursed immediately, and the second tranche of US$50M can be drawn for the development and construction of carbon capture projects with a focus on Canadian projects, subject to approval by both organizations.
  • Svante is constructing a 141,000 sq. ft. facility in Burnaby, BC, Canada, which will produce filters capable of capturing 10 million tonnes of CO2 annually and serve as the company’s global headquarters and R&D center.
  • The proceeds from the first investment tranche will be utilized for commercial development and FOAK project funding.
  • This investment aligns with CGF's mandate by supporting a leading Canadian cleantech company, protecting Canadian IP and jobs, and encouraging the development of Canadian projects and innovation activities.
  • The investment will accelerate the deployment of Svante’s innovative carbon capture technology, which has the potential to significantly reduce global CO2 emissions.
  • This investment marks CGF’s first venture in British Columbia, supporting local jobs in the province and diversifying its investment portfolio.
  • The market for carbon capture and sequestration, and carbon removals, is expanding, with supportive regulations in place in Canada, the USA, and Europe, highlighting the growing demand for emissions reduction and removal technologies.

About CGF

CGF is a $15 billion arm’s length public investment vehicle that helps attract private capital to build Canada’s clean economy by using investment instruments that absorb certain risks, in order to encourage private investment in low carbon projects, technologies, businesses, and supply chains.

CGF makes strategic investments to help Canada meet the following national economic and climate policy goals:

  1. reduce emissions and achieve Canada’s climate targets;
  2. accelerate the deployment of key technologies, such as low-carbon hydrogen and CCS;
  3. scale-up companies that will create jobs, drive productivity and clean growth across new and traditional sectors of Canada’s industrial base;
  4. encourage the retention of intellectual property in Canada; and
  5. capitalize on Canada’s abundance of natural resources and strengthen critical supply chains to secure Canada’s future economic and environmental well-being.

Further information on CGF’s mandate, strategic objectives, investment selection criteria, scope of investment activities, and range of investment instruments can be found on www.cgf-fcc.ca.

About CGF Investment Management

In Budget 2023, the Government of Canada announced that PSP Investments, through a wholly owned subsidiary, would act as investment manager for CGF. CGF Investment Management has been incorporated to act as the independent and exclusive investment manager of CGF.

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815708357/en/

Contacts

Svante Media Relations
Colleen Nitta
Director of Marketing & Communications
cnitta@svanteinc.com
604-970-2813

CGF Media Relations
mediacgf@cgf-fcc.ca

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost

Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 14:30:00 EEST | Press release

Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye